3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Status
Recruiting
2
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Classical hematology
2
Myeloid
1
Genitourinary
1
Gastrointestinal
1
CNS
1
Conditions
Anemia, Refractory, with Excess of Blasts
26
Leukemia, Myeloid, Acute
25
Myelodysplastic Syndromes
21
Venous Thromboembolism
12
Precursor Cell Lymphoblastic Leukemia-Lymphoma
12
Myeloproliferative Disorders
12
Neoplasms
11
Leukemia, Myelomonocytic, Chronic
10
Anemia
10
Lymphoma, Non-Hodgkin
9
Hematologic Neoplasms
9
Primary Myelofibrosis
8
Anemia, Aplastic
8
Thrombocytopenia
7
Leukemia, Lymphocytic, Chronic, B-Cell
7
Hodgkin Disease
7
Multiple Myeloma
6
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
6
Leukemia
6
Febrile Neutropenia
6
Fanconi Anemia
6
Congenital Bone Marrow Failure Syndromes
6
Venous Thrombosis
5
Pulmonary Embolism
5
Myelodysplastic-Myeloproliferative Diseases
5
Lymphoma, Follicular
5
Recurrence
4
Leukemia, Myeloid, Accelerated Phase
4
Leukemia, Biphenotypic, Acute
4
Cytopenia
4
Interventions
N(4)-oleylcytosine arabinoside
1
Aspirin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Hemorrhage
×
Classical hematology
×
90 days
×
Clear all
NCT07410117
2026-05-27
ROXI-CAT-I
Regeneron Pharmaceuticals
Phase 3
Recruiting
1,120 enrolled
NCT05198960
2026-03-20
AVAJAK
University Hospital, Brest
Phase 3
Recruiting
1,308 enrolled